{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:37:07Z","timestamp":1795210627665,"version":"4.10.3"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>Preeclampsia contributes disproportionately to maternal and neonatal morbidity and mortality throughout the world. A critical driver of preeclampsia is angiogenic imbalance, which is often present weeks to months before overt disease. Two placenta-derived angiogenic biomarkers, soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), have proved useful as diagnostic and prognostic tests for preeclampsia. Recently, the U.S. Food and Drug Administration approved the sFlt-1\/PlGF assay to aid in the prediction of preeclampsia with severe features among women with hypertensive disorders of pregnancy at 24\u201334 weeks of gestation. In this narrative review, we summarize the body of work leading to this approval and describe how the sFlt-1\/PlGF ratio may be implemented in clinical practice as an adjunctive measure to help optimize care and to reduce adverse outcomes in preeclampsia.<\/jats:p>","DOI":"10.1097\/aog.0000000000005532","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T22:07:26Z","timestamp":1707862046000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":66,"title":["Angiogenic Biomarkers in Preeclampsia"],"prefix":"10.1097","volume":"143","author":[{"given":"Richard M.","family":"Burwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hellen","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"R1-20250423","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/ajh.2008.20","article-title":"Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004","volume":"21","author":"Wallis","year":"2008","journal-title":"Am J Hypertens"},{"key":"R2-20250423","doi-asserted-by":"crossref","first-page":"f6564","DOI":"10.1136\/bmj.f6564","article-title":"Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis","volume":"347","author":"Ananth","year":"2013","journal-title":"BMJ"},{"issue":"suppl 1","key":"R3-20250423","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/1471-0528.12629","article-title":"Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health","volume":"121","author":"Abalos","year":"2014","journal-title":"BJOG"},{"key":"R4-20250423","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(06)68397-9","article-title":"WHO analysis of causes of maternal death: a systematic review","volume":"367","author":"Khan","year":"2006","journal-title":"Lancet"},{"key":"R5-20250423","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1097\/AOG.0000000000003891","article-title":"Gestational hypertension and preeclampsia. ACOG Practice Bulletin No. 222. American College of Obstetricians and Gynecologists","volume":"135","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R6-20250423","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(10)61351-7","article-title":"Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model","volume":"377","author":"von Dadelszen","year":"2011","journal-title":"Lancet"},{"key":"R7-20250423","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0002-9378(86)90266-8","article-title":"Maternal-perinatal outcome associated with the syndrome of hemolysis, elevated liver enzymes, and low platelets in severe preeclampsia-eclampsia","volume":"155","author":"Sibai","year":"1986","journal-title":"Am J Obstet Gynecol"},{"key":"R8-20250423","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0002-9378(85)80171-X","article-title":"Maternal and perinatal outcome of conservative management of severe preeclampsia in midtrimester","volume":"152","author":"Sibai","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"R9-20250423","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preghy.2019.08.166","article-title":"Management of non-severe pregnancy hypertension: a summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications","volume":"18","author":"Magee","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"R10-20250423","doi-asserted-by":"crossref","first-page":"EVIDoa2200161","DOI":"10.1056\/EVIDoa2200161","article-title":"Circulating angiogenic factor levels in hypertensive disorders of pregnancy","volume":"1","author":"Thadhani","year":"2022","journal-title":"NEJM Evid"},{"key":"R11-20250423","doi-asserted-by":"crossref","first-page":"518.e1","DOI":"10.1016\/j.ajog.2020.11.004","article-title":"Impact of new definitions of preeclampsia at term on identification of adverse maternal and perinatal outcomes","volume":"224","author":"Lai","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20250423","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1600-0412.2011.01111.x","article-title":"How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis","volume":"90","author":"Thangaratinam","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R13-20250423","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJMoa031884","article-title":"Circulating angiogenic factors and the risk of preeclampsia","volume":"350","author":"Levine","year":"2004","journal-title":"N Engl J Med"},{"key":"R14-20250423","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1414838","article-title":"Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia","volume":"374","author":"Zeisler","year":"2016","journal-title":"N Engl J Med"},{"key":"R15-20250423","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/CIRCULATIONAHA.111.054361","article-title":"Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia","volume":"125","author":"Rana","year":"2012","journal-title":"Circulation"},{"key":"R16-20250423","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1056\/NEJMoa055352","article-title":"Soluble endoglin and other circulating antiangiogenic factors in preeclampsia","volume":"355","author":"Levine","year":"2006","journal-title":"N Engl J Med"},{"key":"R17-20250423","doi-asserted-by":"crossref","first-page":"573.e1","DOI":"10.1016\/j.ajog.2022.10.044","article-title":"The additive role of angiogenic markers for women with confirmed preeclampsia","volume":"228","author":"Suresh","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"R19-20250423","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sFlt-1\/PlGF ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","author":"Verlohren","year":"2022","journal-title":"Pregnancy Hypertens"},{"key":"R21-20250423","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/HYPERTENSIONAHA.119.12760","article-title":"Short-term prediction of adverse outcomes using the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor) ratio in Asian women with suspected preeclampsia","volume":"74","author":"Bian","year":"2019","journal-title":"Hypertension"},{"key":"R24-20250423","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41581-019-0119-6","article-title":"Pre-eclampsia: pathogenesis, novel diagnostics and therapies","volume":"15","author":"Phipps","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"R25-20250423","doi-asserted-by":"crossref","first-page":"S1019","DOI":"10.1016\/j.ajog.2020.10.022","article-title":"Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders","volume":"226","author":"Rana","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"R26-20250423","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27-20250423","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1006\/bbrc.1994.1705","article-title":"Specificity of vascular endothelial cell growth factor receptor ligand binding domains","volume":"201","author":"Kendall","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"R28-20250423","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/mend.13.4.0265","article-title":"Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity","volume":"13","author":"He","year":"1999","journal-title":"Mol Endocrinol"},{"key":"R29-20250423","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1095\/biolreprod59.6.1540","article-title":"A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation","volume":"59","author":"Clark","year":"1998","journal-title":"Biol Reprod"},{"key":"R30-20250423","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"R31-20250423","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/10641955.2017.1329430","article-title":"The pathology of eclampsia: an autopsy series","volume":"36","author":"Hecht","year":"2017","journal-title":"Hypertens Pregnancy"},{"key":"R32-20250423","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1172\/JCI6740","article-title":"VEGF(165) mediates glomerular endothelial repair","volume":"104","author":"Ostendorf","year":"1999","journal-title":"J Clin Invest"},{"key":"R33-20250423","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.ajog.2006.01.012","article-title":"Correlations of placental perfusion and PlGF protein expression in early human pregnancy","volume":"194","author":"Welch","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"R34-20250423","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/AOG.0000000000003694","article-title":"Placental growth factor and the risk of adverse neonatal and maternal outcomes","volume":"135","author":"Parchem","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R35-20250423","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1056\/NEJM199707103370201","article-title":"Trial of calcium to prevent preeclampsia","volume":"337","author":"Levine","year":"1997","journal-title":"N Engl J Med"},{"key":"R36-20250423","doi-asserted-by":"crossref","first-page":"161.e1","DOI":"10.1016\/j.ajog.2009.09.016","article-title":"An automated method for the determination of the sFlt-1\/PIGF ratio in the assessment of preeclampsia","volume":"202","author":"Verlohren","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"R37-20250423","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/HYPERTENSIONAHA.113.01787","article-title":"New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia","volume":"63","author":"Verlohren","year":"2014","journal-title":"Hypertension"},{"key":"R38-20250423","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/14767058.2011.589932","article-title":"Maternal plasma concentrations of angiogenic\/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia","volume":"24","author":"Chaiworapongsa","year":"2011","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R39-20250423","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3109\/14767058.2012.713055","article-title":"Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia","volume":"25","author":"Moore","year":"2012","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R40-20250423","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.preghy.2018.05.008","article-title":"Angiogenic biomarkers in triage and risk for preeclampsia with severe features","volume":"13","author":"Rana","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"R41-20250423","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/10641955.2014.982331","article-title":"Influence of the sFlt-1\/PlGF ratio on clinical decision-making in women with suspected preeclampsia: the PreOS study protocol","volume":"34","author":"Hund","year":"2015","journal-title":"Hypertens Pregnancy"},{"key":"R42-20250423","doi-asserted-by":"crossref","first-page":"e0156013","DOI":"10.1371\/journal.pone.0156013","article-title":"Influence of the sFlt-1\/PlGF ratio on clinical decision-making in women with suspected preeclampsia","volume":"11","author":"Klein","year":"2016","journal-title":"PLoS One"},{"key":"R43-20250423","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/HYPERTENSIONAHA.119.12739","article-title":"Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE","volume":"74","author":"Cerdeira","year":"2019","journal-title":"Hypertension"},{"key":"R44-20250423","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.preghy.2021.10.009","article-title":"Cost effectiveness of the sFlt1\/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States","volume":"26","author":"Khosla","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"R45-20250423","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2020.05.013","article-title":"Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia","volume":"21","author":"Suresh","year":"2020","journal-title":"Pregnancy Hypertens"},{"key":"R46-20250423","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/1471-0528.12259","article-title":"Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia","volume":"120","author":"Schnettler","year":"2013","journal-title":"BJOG"},{"key":"R47-20250423","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/uog.15997","article-title":"sFlt-1\/PlGF ratio test for pre-eclampsia: an economic assessment for the UK","volume":"48","author":"Vatish","year":"2016","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R48-20250423","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1080\/14767058.2016.1242122","article-title":"Budget impact analysis of sFlt-1\/PlGF ratio as prediction test in Italian women with suspected preeclampsia","volume":"30","author":"Frusca","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"R49-20250423","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.preghy.2018.04.014","article-title":"Economic evaluation of sFlt-1\/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals","volume":"13","author":"Figueira","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"R50-20250423","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/s12913-018-3406-1","article-title":"Economic assessment of the use of the sFlt-1\/PlGF ratio test to predict preeclampsia in Germany","volume":"18","author":"Schlembach","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"R51-20250423","doi-asserted-by":"crossref","first-page":"4096847","DOI":"10.1155\/2019\/4096847","article-title":"sFlt-1\/PlGF ratio as a predictive marker in women with suspected preeclampsia: an economic evaluation from a Swiss perspective","volume":"2019","author":"Hodel","year":"2019","journal-title":"Dis Markers"},{"key":"R52-20250423","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41440-021-00624-2","article-title":"Economic evaluation of the sFlt-1\/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study","volume":"44","author":"Ohkuchi","year":"2021","journal-title":"Hypertens Res"},{"key":"R53-20250423","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/HYPERTENSIONAHA.120.15146","article-title":"Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study","volume":"77","author":"Dr\u00f6ge","year":"2021","journal-title":"Hypertension"},{"key":"R54-20250423","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","article-title":"Short-term costs of preeclampsia to the United States health care system","volume":"217","author":"Stevens","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R55-20250423","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.preghy.2019.03.002","article-title":"Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: a health economics review","volume":"17","author":"Schlembach","year":"2019","journal-title":"Pregnancy Hypertens"},{"key":"R56-20250423","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMra2109523","article-title":"Preeclampsia","volume":"386","author":"Magee","year":"2022","journal-title":"N Engl J Med"},{"key":"R57-20250423","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"R58-20250423","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/aji.12349","article-title":"Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia","volume":"73","author":"Guseh","year":"2015","journal-title":"Am J Reprod Immunol"},{"key":"R59-20250423","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/HYPERTENSIONAHA.116.07286","article-title":"Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates","volume":"67","author":"Makris","year":"2016","journal-title":"Hypertension"},{"key":"R60-20250423","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1161\/HYPERTENSIONAHA.115.06783","article-title":"Placental growth factor administration abolishes placental ischemia-induced hypertension","volume":"67","author":"Spradley","year":"2016","journal-title":"Hypertension"},{"key":"R61-20250423","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.2015020157","article-title":"Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia","volume":"27","author":"Thadhani","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"R62-20250423","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1161\/CIRCULATIONAHA.111.034793","article-title":"Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"124","author":"Thadhani","year":"2011","journal-title":"Circulation"},{"key":"R63-20250423","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/nbt.4297","article-title":"RNAi modulation of placental sFLT1 for the treatment of preeclampsia","volume":"36","author":"Turanov","year":"2018","journal-title":"Nat Biotechnol"},{"key":"R64-20250423","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","article-title":"Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1","volume":"29","author":"Davis","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"R65-20250423","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/uog.19112","article-title":"Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation","volume":"52","author":"Tan","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R66-20250423","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"R67-20250423","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00404-022-06864-y","article-title":"New advances in prediction and surveillance of preeclampsia: role of machine learning approaches and remote monitoring","volume":"308","author":"Hackel\u00f6er","year":"2023","journal-title":"Arch Gynecol Obstet"},{"key":"R68-20250423","doi-asserted-by":"crossref","first-page":"636.e1","DOI":"10.1016\/j.ajog.2014.11.035","article-title":"Maternal circulating angiogenic factors in twin and singleton pregnancies","volume":"212","author":"Faupel-Badger","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"R69-20250423","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.preghy.2021.02.010","article-title":"Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease","volume":"24","author":"Wiles","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"R70-20250423","doi-asserted-by":"crossref","first-page":"127083","DOI":"10.1155\/2015\/127083","article-title":"Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study","volume":"2015","author":"Rolfo","year":"2015","journal-title":"Dis Markers"},{"key":"R71-20250423","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","article-title":"Differentiating hemolysis, elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period","volume":"78","author":"Burwick","year":"2021","journal-title":"Hypertension"},{"key":"R72-20250423","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.preghy.2018.02.007","article-title":"Thrombotic microangiopathies of pregnancy: differential diagnosis","volume":"12","author":"Gupta","year":"2018","journal-title":"Pregnancy Hypertens"},{"key":"R73-20250423","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/AOG.0000000000003570","article-title":"Pregnancy prolongation after eculizumab use in early-onset preeclampsia","volume":"134","author":"Lu","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R74-20250423","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/jcp.2008.056929","article-title":"Clinical audit in the laboratory","volume":"62","author":"Erasmus","year":"2009","journal-title":"J Clin Pathol"},{"key":"R75-20250423","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1515\/cclm-2022-1071","article-title":"Improved implementation of medical tests: barriers and opportunities","volume":"61","author":"St John","year":"2023","journal-title":"Clin Chem Lab Med"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:02:50Z","timestamp":1745427770000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/AOG.0000000000005532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000005532","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"2023-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}